Moexipril

Moexipril is an ACE inhibitor used to treat high blood pressure. Here are the supported uses based on the available product evidence:

• High blood pressure (hypertension): Moexipril Hydrochloride tablets are indicated for adults with hypertension, used alone or alongside a thiazide diuretic when needed for additional blood pressure control.

Moexipril is a prodrug, which means it isn't active until your body converts it to its working form — moexiprilat. Moexiprilat blocks ACE (angiotensin-converting enzyme), an enzyme that produces angiotensin II, a powerful chemical that tightens blood vessels and raises blood pressure. By blocking this enzyme, moexiprilat lets blood vessels relax, reduces blood pressure, and slightly lowers the hormone aldosterone — which causes your body to hold onto salt and fluid.

It's worth knowing that moexipril, like other ACE inhibitors, is less effective at lowering blood pressure in Black patients — who tend to have lower renin levels — than in non-Black patients. Effectiveness was not meaningfully affected by age, sex, or body weight in clinical trials.

Moexipril Hydrochloride tablets are taken by mouth, typically once daily, though twice-daily dosing may be used if blood pressure is not well controlled toward the end of the dosing interval. The tablets should be taken on an empty stomach, about one hour before a meal — food can reduce the amount of drug absorbed by 40–80%, so this timing matters. For patients also taking diuretics, the diuretic should ideally be stopped a few days before starting moexipril to reduce the risk of a sharp blood pressure drop. Always take it exactly as your prescriber instructs.

Most people tolerate moexipril well; reported side effects were generally mild and short-lived. Common ones include:

Get medical help right away for signs of angioedema (swelling of the face, lips, tongue, or throat), significant drop in blood pressure (fainting, severe dizziness), yellowing of the skin or eyes, or markedly decreased urination — these are serious reactions that need prompt attention.

• Fetal toxicity (most critical): Moexipril can cause serious injury or death to a developing baby. Stop immediately if pregnancy is detected and contact your doctor right away.
• Angioedema: Swelling of the face, lips, tongue, throat, or intestines can occur and can be life-threatening. Anyone with a history of ACE inhibitor-related angioedema must not take moexipril. Black patients face a higher risk of angioedema.
• Low blood pressure (hypotension): Risk is highest at the start of therapy, especially in people who are volume-depleted, on diuretics, or have heart failure or kidney disease. Lie down and seek help if you feel faint.
• Kidney function changes: Moexipril can worsen kidney function, particularly in people already on diuretics or with underlying kidney disease. Kidney function should be monitored.
• High potassium (hyperkalemia): Moexipril can raise potassium levels; risk goes up if you're also taking potassium supplements or potassium-sparing diuretics.
• Liver failure (rare): ACE inhibitors have rarely caused serious liver damage. Report any jaundice or markedly elevated liver enzymes promptly.
• Low white blood cell count (neutropenia/agranulocytosis): Rare, but more likely in patients with kidney disease or collagen-vascular disease such as lupus. Blood count monitoring may be appropriate.

Several medications and drug classes can interact meaningfully with moexipril:

• Diuretics (water pills): Can cause a steep blood pressure drop when moexipril is started; the diuretic should ideally be paused first or the starting dose reduced.
• Potassium-sparing diuretics or potassium supplements: Raise the risk of dangerously high potassium levels (hyperkalemia); use cautiously and monitor potassium.
• Lithium: Moexipril can raise blood lithium levels, increasing toxicity risk; frequent monitoring is needed.
• NSAIDs and COX-2 inhibitors (e.g., ibuprofen, naproxen, celecoxib): May blunt moexipril's blood pressure effect and can harm kidney function, especially in older or volume-depleted patients.
• Aliskiren: Must not be combined with moexipril in patients with diabetes; avoid in patients with kidney disease.
• Other RAS-blocking drugs (angiotensin receptor blockers): Combining two drugs that block the renin-angiotensin system raises the risk of low blood pressure, high potassium, and kidney problems.
• Injectable gold (sodium aurothiomalate): Rare flushing, nausea, and low blood pressure reactions (nitritoid reactions) have been reported.

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

• Do not take moexipril if you have ever had angioedema (severe swelling) caused by an ACE inhibitor, or if you are allergic to moexipril or similar drugs.
• Do not combine moexipril with aliskiren if you have diabetes; also avoid this combination if you have kidney disease.
• Pregnancy: Moexipril must be stopped as soon as pregnancy is confirmed — it can cause serious fetal harm or death. Use effective contraception while taking this medication.
• Kidney disease: A lower starting dose is required; the drug stays in your body longer when kidney function is reduced. Dose titration must be done carefully.
• Liver disease: Moexipril levels are altered in people with cirrhosis; use with caution and close monitoring.
• Older adults: Drug levels (as moexiprilat) run about 30% higher in older men; monitor closely for side effects such as low blood pressure.
• Collagen-vascular diseases (e.g., lupus, scleroderma) with kidney disease: Higher risk of a dangerous drop in white blood cells; blood count monitoring may be recommended.
• Dialysis patients or those undergoing allergy desensitization: Serious anaphylactoid reactions have been reported with ACE inhibitors in these situations.
• Heart failure or ischemic heart disease: Extra caution needed — excessive blood pressure lowering can trigger serious cardiovascular events; start under close medical supervision.

Human overdose experience with moexipril is very limited, but the main expected effect is a significant drop in blood pressure (hypotension). If an overdose is suspected, lying flat and receiving intravenous fluids (normal saline) is the primary supportive treatment described in the label. Kidney function and potassium levels should also be monitored.

Moexipril starts lowering blood pressure within about one hour of a dose, with the peak effect occurring between three and six hours after dosing. At doses of 15 mg or more, it sustains ACE inhibition of 80–90% for up to 24 hours. During long-term therapy, the full blood pressure-lowering effect generally becomes apparent within two to four weeks of starting treatment and has been shown to continue for up to 24 months. The blood pressure-lowering effect is less pronounced in Black patients compared to non-Black patients.

After you swallow moexipril, your body converts it into the active form, moexiprilat, fairly quickly — but food dramatically reduces how much is absorbed (by 40–80%), so it must be taken on an empty stomach. The active form reaches peak blood levels in about 1.5 hours and is cleared with a functional half-life (the time for blood levels to fall by half) of roughly 12 hours, allowing once-daily dosing. Moexiprilat is mainly eliminated in the feces and, to a lesser extent, in urine; in people with reduced kidney function, the drug stays in the body significantly longer — up to 3 to 4 times as long at low creatinine clearances — requiring dose adjustments.

Store, tightly closed, at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) . Protect from excessive moisture. dispense in tight containers as described in USP-NF.